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The prevalence of diabetes worldwide is continually increas-
ing, and even more people are affected by prediabetes. As a re-
sult of scientific and economic growth, the number of diabetes 
patients has increased rapidly from less than 1% in the 1970s 
to more than 10% in the mid-1990s; in Korea, the incidence is 
projected to be 15% to 20% by 2030 [1]. Before 1996, only sul-
fonylureas and insulin were available for the treatment of type 
2 diabetes mellitus (T2DM). Since then, drugs of several other 
classes have been developed. 
  Hypoglycemic agents in T2DM should be chosen based upon 
the medical needs and treatment goals of the patient, potency 
of the agent in achieving treatment goals, tolerability, side ef-
fects, cost-effectiveness, ease of administration, and other ben-
eficial extraglycemic effects. 
  The biguanide drug metformin was introduced for the treat-
ment of T2DM in Europe in 1957 but was not approved in the 
United States until 1995 because of fear of lactic acidosis. How-
ever, recent studies have suggested that metformin is safe un-
less the patient’s estimated glomerular filtration rate falls to 
<30 mL/min [2]. The drug’s major effect is to decrease hepatic 
glucose output and lower fasting glycemia [3]. In the United 
Kingdom Prospective Diabetes Study (UKPDS), metformin 
was shown to reduce cardiovascular events [4]; the risk of pro-
gression from prediabetes to T2DM decreased by 31% in the 
Diabetes Prevention Program (DPP) cohort [5]. Given these 
benefits, metformin should be considered a first-line agent in 
the treatment of T2DM. 
  The thiazolidinediones (TZDs) rosiglitazone and piogli-
tazone are approved for monotherapy and combination treat-
ment of T2DM. These medications increase the sensitivity of 
muscle, fat and liver to both endogenous and exogenous insu-
lin (“insulin sensitizers”) [6]. In addition, TZDs have been 
shown to preserve or improve β-cell secretory function in pa-
tients with T2DM. TZD monotherapy lowers A1C levels by 
0.5 percent to 1.4 percent. The most common side effects of 
TZDs are weight gain and fluid retention, along with periph-
eral edema and an increased risk for congestive heart failure 
[7,8]. Several meta-analyses have suggested a 30% to 40% rela-
tive increase in the risk for myocardial infarction [9,10] with 
rosiglitazone; however, reanalysis by the Food and Drug Ad-
ministration found no significant increase in serious ischemia 
in patients treated with rosiglitazone [11]. In contrast, the Pro-
spective Pioglitazone Clinical Trial in macrovascular events 
(PROactive) demonstrated no significant effects of pioglitazone 
compared with placebo on primary cardiovascular disease 
outcome [12]. A retrospective analysis of the Veterans Affairs 
Diabetes Trial (VADT) cohort, which included nearly 40,000 
patients treated with metformin, sulfonylurea or TZDs, found 
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no difference in cardiovascular outcomes among users of the 
three classes of drugs [13]. Although the meta-analyses dis-
cussed above are not conclusive regarding the potential car-
diovascular risk associated with this medication, rosiglitazone 
should be used with caution. 
  The sulfonylureas are very commonly used because they are 
readily available, affordable and have convenient dosing in-
structions [14]. Although the onset of the glucose-lowering ef-
fect of sulfonylurea monotherapy is relatively rapid compared 
with TZDs, the glycemic durability is not as good as mono-
therapy with a TZD or metformin [15]. A recently published,   
observational cohort study also stated that in a standard clini-
cal setting, insulin secretagogues are associated with increased 
failure rates in comparison with metformin, even after adjust-
ing for controllable confounders [16]. Sulfonylureas have a 
primary failure rate of 20% and a secondary failure rate of 5% 
to 10% per year of treatment [17]. 
  The Practical Evidence of Anti-diabetic Monotherapy 
(PEAM) study, which evaluated the efficacy of glimepiride, 
metformin and rosiglitazone as an initial treatment for drug-
naïve T2DM, was a 48-week randomized, controlled study that 
included 349 Korean patients and was conducted by Yoon et 
al. [18]. This study found that there were no statistical differ-
ences in the efficacy of these drugs as monotherapy in drug-
naïve Korean T2DM patients. In concordance with previous 
reports of anti-diabetic regimens [3,6,14], the main side effect 
with metformin was diarrhea, edema and weight gain with 
rosiglitazone, and symptomatic hypoglycemia and weight gain 
with glimepiride. Yoon et al. did not observe the time course 
of metabolic changes during the study. Assessing metabolic 
changes that include lipid parameters is important in evaluat-
ing the metabolic effect of anti-diabetic agents and a multi-fac-
torial intervention as a diabetic treatment strategy for improv-
ing cardiovascular outcome. Additionally, this study was de-
signed to use rosiglitazone, which has been practically thrown 
out in market in recent years. It is not clear whether the sched-
uled up titration performed in the present study is a suitable 
and optimal method for Koreans. A relatively high drop-out 
rate was also observed. Therefore, these limitations can lessen 
the value of the information gained from this study in select-
ing an oral hypoglycemic agent in Korean diabetic patients. 
Despite these limitations, the importance of this study is that it 
is the first randomized, controlled trial to evaluate the efficacy 
of commonly used oral hypoglycemic agents in Korean T2DM 
patients. The study was well-designed and is one of the few 
studies in which commonly used anti-diabetic drugs were di-
rectly compared among drug-naïve diabetic patients.
  Newer agents including incretins are less likely to produce 
adverse effects such as symptomatic hypoglycemia, are cur-
rently being broadly used in drug-naïve T2DM patients. Sev-
eral studies evaluating the efficacy and beneficial and adverse 
effects of these agents are currently ongoing worldwide. Future 
studies are therefore needed to evaluate these new agents as a 
monotherapy in Korean T2DM patients. While this study 
found that about 30% of participants remained in an inade-
quate glycemic control state, a lack of consensus remained in 
regard to the choice of a combination regimen to optimize gly-
cemic control. As the authors have noted, a more detailed sub-
group analysis and further investigation, particularly as it re-
lates to the combination regimens, are required. 
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